Concepedia

Kyle R. Brimacombe

KR

Statistics

Publications

44

Citations

4.8K

H-Index

29

Active since

2004

Affiliations

National Institutes of Health(Current)

National Center for Advancing Translational Sciences

National Cancer Institute

Dana-Farber Cancer Institute

Massachusetts Institute of Technology

Kyle R. Brimacombe is an author at National Institutes of Health specializing in pharmacology, drug discovery, and medicinal chemistry.

ORCID

Publications per year

2004–2021

44

Publications

44

Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis

Dimitrios Anastasiou, Yimin Yu, William J. Israelsen et al. · Nature Chemical Biology · 2012 · 825 citations · Full text

, , +15

Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors

Anju Singh, Sreedhar Venkannagari, Kyu Hee Oh et al. · ACS Chemical Biology · 2016 · 613 citations

, , +16

A PHGDH inhibitor reveals coordination of serine synthesis and one-carbon unit fate

Michael E. Pacold, Kyle R. Brimacombe, Sze Ham Chan et al. · Nature Chemical Biology · 2016 · 589 citations · Full text

, , +14

Drug-based modulation of endogenous stem cells promotes functional remyelination in vivo

Fadi J. Najm, Mayur Madhavan, Anita Zaremba et al. · Nature · 2015 · 422 citations

, , +12

Assay Guidance Manual [Internet]

Sarine Markossian, A Grossman, Kyle R. Brimacombe et al. · 2004 · 287 citations

, , +17

1–5 of 44